Recent Finacing
Recent Raise
Emalex Biosciences develops ecopipam, a D1 receptor antagonist for Tourette syndrome and childhood-onset fluency disorder, and conducts Phase 2/3 clinical trials including pediatric and adolescent populations.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Emalex Biosciences.
